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Structure-Guided Design of Peptides as Tools to Probe the
Protein–Protein Interaction between Cullin-2 and
Elongin BC Substrate Adaptor in Cullin RING E3 Ubiquitin
Ligases
Teresa A. F. Cardote and Alessio Ciulli*[a]
Cullin RING E3 ubiquitin ligases (CRLs) are large dynamic multi-
subunit complexes that control the fate of many proteins in
cells. CRLs are attractive drug targets for the development of
small-molecule inhibitors and chemical inducers of protein
degradation. Herein we describe a structure-guided biophysical
approach to probe the protein–protein interaction (PPI) be-
tween the Cullin-2 scaffold protein and the adaptor subunits
Elongin BC within the context of the von Hippel-Lindau com-
plex (CRL2VHL) using peptides. Two peptides were shown to
bind at the targeted binding site on Elongin C, named the
“EloC site”, with micromolar dissociation constants, providing a
starting point for future optimization. Our results suggest li-
gandability of the EloC binding site to short linear peptides,
unveiling the opportunity and challenges to develop small
molecules that have the potential to target selectively the
Cul2-adaptor PPI within CRLs.
Cullin RING E3 ubiquitin ligases (CRLs) are key machineries of
the ubiquitin proteasome system as they are responsible for
catalyzing the final step in the ubiquitination cascade, in which
a ubiquitin molecule is transferred to the substrate.[1] CRLs, of
which over 230 are estimated in human cells, are responsible
for approximately 20% of the ubiquitin-dependent protein
turnover in cells, being implicated in a number of cellular pro-
cesses across different organisms.[2] The significant roles of
CRLs in several biological processes and human diseases has
rapidly emerged, in particular in cancer, where the genes en-
coding for E3 ligase subunits and their native substrates are
often found as oncogenes or tumor suppressors.[3] Currently,
much focus is directed toward targeting E3 CRLs with small
molecules, such as inhibitors, to block the ligase activity;[4] mo-
lecular glues, to redirect E3 CRL activity toward neo-sub-
strates;[5] and bivalent PROTACs, to induce targeted protein
degradation.[6, 7] These chemical modalities motivate the grow-
ing interest in studying this class of enzymes. While E3 inhibi-
tors, molecular glues and PROTACs have been widely reported,
to our knowledge there are only a few examples of small mol-
ecules developed to disrupt inter-subunit assembly within
CRLs.[8, 9]
Our work focused on probing a particular protein–protein
interaction (PPI) in the CRL2VHL ligase. The central scaffold of
the VHL ligase is Cullin-2 (Cul2), which recruits at the N-termi-
nal domain the von Hippel-Lindau protein (pVHL) as substrate
receptor, through an adaptor subunit constituted by Elongin B
(EloB) and Elongin C (EloC) and at the C-terminal domain the
RING box protein, Rbx1 (Figure 1B). We were interested in an
epitope of the PPI between Cul2 and the receptor-adaptor tri-
meric subunit composed by pVHL, EloB and EloC (VBC). This
PPI has been described as comprising three main points of in-
teraction.[10,11] The first crystal structure (Ref. [10]) comprised
VBC bound to the first helical bundle of Cul2NTD, whereas a
recent crystal structure (Ref. [11]) reported by us comprises the
whole CRL2VHL complex. The latter work unveiled the impor-
tance of hydrophobic residues for the tight binding affinity ob-
served between VBC and Cul2 (Kd=42 nm). In this work, we fo-
cused our attention on the contact surface between the N-ter-
minal tail of Cul2 and EloC, which we refer to as EloC site.
Targeting PPIs with small molecules provides many opportu-
nities for basic biology and molecular therapeutics, but the
physicochemical nature of these interfaces turns the ability to
modulate them into a great challenge.[12–14] Therefore, the
identification and development of binding ligands to protein
surfaces, whether direct or allosteric modulators of PPIs, re-
mains a difficult and unsolved problem. Fortunately, much
progress has been made in recent years in this direction. In
particular, it is becoming evident that the development of
drug-like PPI inhibitors, and small-molecule ligands to protein
surfaces, can greatly benefit from the availability of a peptidic
ligand to that binding site, which could be from the natural in-
teracting partner or from synthetic sources.[15]
We hypothesized that Cul2-derived peptides binding to the
EloC site could provide valuable insight on how to target the
Cul2-VBC PPI. Previous work in our research group has led to
the development of potent small-molecule disruptors of the
pVHL-HIF-1a PPI based on the structure of pVHL bound to a
19-mer parental peptide derived from HIF-1a.[16–18] It was there-
fore an attractive strategy to explore the potential to apply a
similar approach to other non-HIF binding surfaces on VBC.
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Such peptidic ligands could inform on the nature and details
of key interactions essential to achieve affinity at the targeted
binding site. They could also provide useful displacement tools
to ensure specificity of interaction of compound series in
ligand development campaigns. Furthermore, peptides are in-
teresting candidates as PPI modulators themselves, presenting
a number of advantages over non-peptidic small molecules:
biocompatibility, and low toxicity to the organism; chemical
flexibility, such as the ability to adapt to large and often flexi-
ble surfaces; modularity, thus enlarging the structural diversity,
enhancing selectivity and leading to high potency.[19]
Considering the important role of the N-terminal tail of Cul2
in establishing the interaction with VBC (Figure 1), it was hy-
pothesized that short peptides able to reproduce this tail
could recapitulate the interaction, providing tools to develop
chemical probes and target this PPI. Based on the structural
analysis of the Cul2-VBC interface, we first aimed to recapitu-
late the interaction using N-terminal Cul2 peptides varying
from three to eleven residues. The peptides were synthesized
and seven of the nine peptides were tested for binding to VBC
by Biolayer Interferometry (BLI) (the 9-mer and 11-mer pep-
tides could not be tested because they formed a white precipi-
tate in the conditions of the experiment). The results showed
that at least six amino acids were required to observe binding
to VBC. The binding event was recapitulated with the 6-, 7-, 8-
and 10-mer peptides; nevertheless, the binding affinities deter-
mined were quite weak (Kd in the millimolar range, Figure 2).
Thus, the next step was to enhance the binding affinity of the
peptides toward VBC.
Considering the 8-mer peptide (MSLKPRVV) had the best fit-
ting, tighter binding affinity and reproducibility in the previous
BLI assay, it was chosen as template for an alanine scanning to
identify hotspots in the 8-mer peptide. By replacing, one at a
time, all the amino acid residues by an alanine residue we ob-
served that upon replacement of Pro5 or Arg6, the binding of
the peptide toward VBC was totally lost (Figure 2). This was in
agreement with the structural analysis of the Cul2-VBC com-
plex,[10] which suggests that Pro5 is responsible for the folding
of the N-terminal tail of Cul2 upon itself and Arg6 is responsi-
ble for keeping this conformational arrangement by establish-
ing intramolecular hydrogen bonds with the carbonyl groups
from the backbone of Ser2 and Lys4. Replacing Lys4 with ala-
nine resulted in a 10-fold decrease in the binding affinity but
the replacement of other amino acids in the peptide with ala-
nine did not seem to perturb the interaction as much. The ala-
nine scanning results also implied that the leucine residue, of
which the side chain inserts into the EloC site could be re-
placed without significant loss of binding affinity.
From the results of the initial screen we learned that: 1) the
preferential size of the peptide comprised eight amino acids;
2) Pro5 and Arg6 were critical to assure binding to VBC; and
3) Leu3 could be replaced without major loss of binding affini-
ty. Thus, we employed a structure-based approach to enhance
the affinity of the 8-mer peptide, by replacing the leucine with
amino acids presenting bulkier side chain groups. A small li-
brary of 8-mer peptides containing a set of natural and non-
natural amino acids replacing Leu3 was designed and tested
for binding to VBC. The criteria for choosing these amino acids
was to modulate the bulkiness of the side chain group, for ex-
ample, we chose phenylalanine and tert-butylglycine, among
Figure 1. A) N-terminal tail in the Cullin family. The extension of the N-terminal tail, residues ahead of the first a-helix, is variable across the Cullins and plays
different roles in the respective PPIs. B) The CRL2VHL complex. Crystal structure of the CRL2VHL complex (PDB ID: 5N4W)[11] composed by pVHL as receptor sub-
unit, EloB and EloC as adaptor subunit, Cul2 as scaffold subunit, and Rbx1 as RING finger domain. Close-up view of the PPI between the N-terminal tail of
Cul2 and VBC.
Figure 2. Biolayer interferometry data of N-terminal Cul2 peptides versus
VBC. A) Binding affinities (Kd values) obtained from the BLI experiments.
B) Representative sensorgram of the 8-mer peptide titrated against VBC.
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others, to increase the volume occupied by the side chain. As
before, the peptides were initially tested by BLI for binding to
VBC (Table 1). The BLI results showed that the EloC pocket
could accommodate all the derivative peptides, except when
leucine was replaced by tryptophan, which was probably
overly bulky and was found to decrease the binding affinity
relative to the parental peptide. In addition, it was also ob-
served that the replacement of leucine with tert-butylglycine
and dimethylcysteine (peptides G and J, respectively) led to
the dissociation constant breaking into the micromolar range.
Particularly for peptide J, the Kd value determined by BLI was
0.3:0.1 mm, which represents a 6-fold improvement in re-
gards to the parental peptide A. These results encouraged fur-
ther in-depth characterization of peptide J, with the aim to
better understand its binding interaction.
The binding of peptide J to VBC was characterized further
by other biophysical techniques in addition to BLI, namely iso-
thermal titration calorimetry (ITC), AlphaLISA competition
assay, and protein-observed nuclear magnetic resonance
(NMR), which all showed consistent results. Titration of peptide
J into VBC by ITC resulted in the determination of Kd=5.28V
10@4:0.65V10@4m (Figure 3B). This three-digit micromolar Kd
corroborated the Kd value obtained by BLI (Figure 3A). In the
AlphaLISA assay, peptides A and J were used to disrupt the
native interaction between VBC and Cul2. Both peptides A and
J were found to displace Cul2 (Figure 3C).
The IC50 determined for peptide J in the AlphaLISA displace-
ment assay was 0.22 mm, a value similar to the Kd values for
direct binding measured by ITC and BLI. However, the AlphaLI-
SA assay could not distinguish the binding of peptide J from
peptide A, which had shown 10-fold weaker binding affinity by
BLI, presumably due to differences between the two assays.
Nonetheless, the AlphaLISA results clearly validated the bind-
ing to the Cul2 binding site. Finally, we performed chemical
shift perturbation (CSP) experiments by protein-observed NMR
and the results suggested that the peptide was binding to
VBC. Additionally, the data was in agreement with the AlphaLI-
SA, suggesting that peptide J was binding to the EloC pocket
(Figure 4). Upon binding to a certain area of the protein, the
peptide changes the chemical environment of the residues
that surround it. These changes in the chemical environment
are registered as peak shifting or disappearance. The residues
affected by the binding of the peptide were identified based
on the peak assignment available for VBC (provided by Dr.
Mark Bycroft, Cambridge).[20] It was remarkable that whilst
some peaks were undeniably affected, others remained con-
stant. Mapping the disturbed residues on the structure sug-
gested that the residues more affected by the presence of the
peptide were near the EloC pocket (Figure 4B). There were
also some other peaks shifting that correspond to residues in
different areas of the protein. It is expected that amino acids
at a certain distance from the binding site might rearrange
upon binding of a ligand and, hence, promote shifts.
The biophysical characterization suggested moderate bind-
ing to VBC and it disclosed the opportunity to develop these
Cul2 peptides into high-affinity binders. The strength of the in-
teraction was boosted about 4-fold simply by increasing the
volume of the side-chain fitting the EloC site. It is anticipated
that the structure of Cul2 N-terminal tail bound to VBC can
differ significantly when in the context of an 8-mer peptide or
in the context of the full-length protein. The structural knowl-
edge of the binding mode of peptide J in complex with VBC
would help to inform molecular design to enhance binding.
Considering this, efforts were taken into co-crystallizing pep-
tide J with VBC, however, to date this has not been achieved.
In conclusion, it has proven challenging to target this partic-
ular PPI using peptides. The VBC-Cul2 interaction appears to
be a tertiary PPI,[21] involving multiple epitopes. In fact, as ob-
served in the crystal structure, the interaction is directed by
three points of contact between pVHL, Cul2 and EloC. Despite
Table 1. Results of the BLI experiment with the peptide variants replacing
Leu3 (highlighted in the structure below).
Peptide Leu3 replacement Kd [mm]
A leucine 2.0:0.2
B tryptophan 18:1
C phenylalanine 3.1:0.2
D tyrosine 7.4:0.4
E norleucine ND[a]
F norvaline 1.9:0.2
G tert-butylglycine 0.9:0.1
H phenylglycine 2.1:0.6
I cyclohexhylglycine 8.9:0.7
J dimethylcysteine 0.3:0.1
K thioproline 2.2:0.4
[a] The Kd value of peptide E could not be determined because the fitting
function was not adequate for the data, suggesting that other effects in
addition to genuine and reversible 1:1 binding likely account for the ob-
served signal.
ChemMedChem 2017, 12, 1491 – 1496 www.chemmedchem.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1493
Communications
the N-terminal tail of Cul2 being important for the specificity
of the interaction, by itself it could not drive a tight binding
event. Therefore, peptides that target only one of these inter-
action sites would likely not be able to mimic the native inter-
action and thus would not block the PPI site effectively. Other
drug discovery tools such as peptide stapling,[22] or tether-
ing,[12] for example, might be helpful toward this goal. Another
approach to target this kind of PPIs could be the use of bicy-
Figure 3. Biophysical characterization of peptide J binding to VBC. A) BLI results. Peptide J was titrated against VBC and a Kd value was determined based on
the fitting of the response data points. B) ITC experiment. Peptide J (5 mm) was titrated against 100 mm VBC at 298 K. C) AlphaLISA results of the titration of
peptides A and J in a competition experiment to displace Cul2.
Figure 4. Chemical shift perturbation analysis by NMR spectroscopy. A) HSQC spectra with zoom in regions where it is possible to observe peaks being affect-
ed by the binding of peptide J and peaks not being affected. B) Mapping of CSP in VBC. Affected residues are shown in grey. Residues in EloC pocket have
shifted, suggesting binding of the peptide in the expected binding site. Residues marked in pink could not be identified in our spectra, thus it is not clear
whether the chemical shifts from those residues have been perturbed in the presence of the peptide.
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clic peptides as they cover a large surface area and are able to
closely mimic PPI features.[23]
Our work demonstrates how demanding it can be to target
extended PPI regions, as opposed to well-defined binding-
sites. In this particular case, it suggests that the narrow and
merely hydrophobic nature of the EloC site make it a challeng-
ing target site. The gained knowledge and tools will neverthe-
less inform future development of small molecules that could
target this specific PPI and could be used as chemical probes
to study Cul2-dependent CRLs.
Experimental Section
Protein expression : VBC ternary complex was described previous-
ly.[17] BL21(DE3) E. coli cells were co-transformed with the plasmid
for expression of pVHL/SOCS2 and the bi-cistronic pDUET plasmid
for expression of EloBC. A single colony of transformant was used
to inoculate LB media for bacterial culture. Protein expression was
induced with 0.3 mm IPTG (when OD600 reached 0.8) at 24 8C for
18 h. Co-expression of these proteins resulted in the formation of
the respective trimeric complex (VBC) that was then purified by
two steps of affinity chromatography, followed by ion-exchange
chromatography and finally by size-exclusion chromatography. The
His-tag was cleaved between the two affinity chromatography
steps with TEV protease. Following this protocol the yield of pro-
tein was about 15–20 mg per liter of culture. For the expression of
2H,15N-VBC, the LB media was replaced with E. coli-OD2 enriched
media (Silantes) and the yield dropped to 4 mgL@1.[24]
Peptide synthesis and purification : the peptides were synthesized
in an INTAVIS RespepSL automated peptide synthesizer using solid
phase Fmoc chemistry. The peptides were cleaved from the resin
using a solution of TFA, water and triisopropylsilane (TIS)
(92.5:2.5:5). The peptides were obtained as C-terminal amides and
were purified by HPLC in basic conditions (0.1% NH4OH) in a gradi-
ent of 0–100% of acetonitrile in water over 15 minutes. The purity
and identity of the peptides was determined by LC–MS.
Biolayer interferometry : BLI experiments were performed in an
Octet RED384 (FkrteBio). Biotinylated VBC (25 mgmL@1) was immo-
bilized on Super Streptavidin-coated biosensor (FkrteBio). The ex-
periments were conducted at 25 8C, in 20 mm HEPES pH 7.6,
100 mm NaCl, 1 mm DTT and 0.02% (v/v) Tween-20 buffer. The re-
sponse of the reference tips was subtracted from the signal to ac-
count for unspecific binding. The data points were fitted using a
1:1 model.
Isothermal titration calorimetry : ITC experiments were carried out
in an ITC200 microcalorimeter (Malvern). All protein solutions were
dialyzed into 100 mm Bis-tris propane pH 8.0, 50 mm NaCl, 2 mm
TCEP prior to the titrations. The peptide (5 mm) was titrated into
VBC (100 mm). The titrations consisted of 19 injections of 2 mL each
(120 sec spacing and 600 rpm stirring speed) at 30 8C.
AlphaLISA : Anti-His6 acceptor beads and Streptavidin donor beads
(PerkinElmer) were used. The competition assay was performed in
a 384-well plate by mixing V6VHisBC (500 nm) and biotinylated
Rbx1-Cul2 (150 nm) and titrating the competitor (peptide). The
final volume of each well was 20 mL. The plate was then read in a
PHERAstar FS (BMG LABTECH). Each of the competitors was titrated
in quadruplicate. The fitting and IC50 determination were per-
formed in GraphPad Prism 7 (GraphPad Software, La Jolla, CA,
USA).
NMR spectroscopy : NMR experiments were carried out in an AV-
500 MHz Bruker spectrometer equipped with a 5 mm CTPXI 1H-13C/
15N/D Z-GRD cryoprobe. The total volume of the sample was
200 mL and the experiments were performed in a capillary tube
containing 100 mm 2H,15N-VBC samples in a buffer of 20 mm
KH2PO4 pH 7.0, 50 mm KCl, 1 mm DTT, 0.02% NaN3 and 15% of
D2O. The 2D
1H, 15N-HSQC-TROSY spectra (in the presence or ab-
sence of peptide) were recorded with 32 scans and acquisition
times of 200 ms for 1H and 100 ms for 15N, at 30 8C. The spectra
were analyzed in CCP NMR[25] and the chemical shift perturbation
(CSP) were calculated according to the following equation:
CSP ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
DH2 þ DN> 0:14ð Þ2
p
, where DH is the change in proton
chemical shift, DN is the change in nitrogen chemical shift and
0.14 is a scaling factor required to account for the difference in the
range of amide proton and amide nitrogen chemical shifts.[26] A
CSP was considered when it was greater than (x þ 2s. The back-
bone assignment of VBC has been made available as by Dr. Mark
Bycroft (Laboratory of Molecular Biology, MRC, Cambridge, UK) and
shared as a gift.
Supporting Information : The raw BLI data are provided in the
Supporting Information.
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